Remove 2020 Remove Blogging Remove Equity Remove San Diego
article thumbnail

Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

Xconomy

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. There, topics once as unanticipated as the remote nature of the meeting shared top billing: COVID-19 and racism.

San Diego 121
article thumbnail

Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More

Xconomy

Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biopharma Execs Remain Optimistic Despite Political Headwinds

Xconomy

Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. Nearly half of respondents believe that political and policy uncertainty present the greatest risks in 2020, with the latest Brexit developments and approaching UK and US elections seeing concerns around political volatility growing.

Pricing 78
article thumbnail

California Accelerators Enroll Startups Targeting Cannabis Industry

Xconomy

On Monday, nine startups began a 16-week program at Canopy San Diego , a new accelerator program for seed-stage companies developing new technologies, products, and services to support the legal cannabis industry. By 2020, the cannabis industry is projected to hit $21.8 billion , according to ArcView Market Research.